Argenx's FB102 meets primary endpoint in Phase 2 celiac disease study; company to advance into Phase 3

Argenx's FB102 met its primary endpoint in a Phase 2 celiac disease study versus placebo with no new safety signals. The company will advance the first-in-class CD122 inhibitor into Phase 3 development.

Detected & updated continuously · Source: Nebula